Search

Your search keyword '"Richard J. Lin"' showing total 4 results
Start Over Author "Richard J. Lin" Journal haematologica
4 results on '"Richard J. Lin"'

1. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

Author

Richard J. Lin, Colette N. Owens, Esther Drill, Augustine Iannotta, Mayan Oliveros, Dylan L. Schick, Ariela Noy, John F. Gerecitano, Pamela R. Drullinsky, Philip C. Caron, Anita Kumar, Matthew J. Matasar, Craig Moskowitz, Beatriz Korc-Grodzicki, Andrew D. Zelenetz, Gilles A. Salles, and Paul A. Hamlin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as functional limitation, multimorbidity, or cognitive deficits. In this prospective pilot study, we evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL, defined by either age ≥70 years or age 60-70 years with Karnofsky performance scale (KPS)

Published
2021
Full Text
View/download PDF

2. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Author

Richard J. Lin, Stephanie M. Lobaugh, Martina Pennisi, Hei Ton Chan, Yakup Batlevi, Josel D. Ruiz, Theresa A. Elko, Molly A. Maloy, Connie L. Batlevi, Parastoo B. Dahi, Sergio A. Giralt, Paul A. Hamlin, Elena Mead, Arela Noy, M. Lia Palomba, Bianca D. Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Beatriz Korc-Grodzicki, Soo Jung Kim, Mari Lynne Silverberg, Chelsea A. Brooklyn, Sean M. Devlin, and Miguel-Angel Perales

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2020
Full Text
View/download PDF

3. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Author

Yakup Batlevi, Soo Jung Kim, Molly Maloy, Connie Lee Batlevi, Arela Noy, Theresa A. Elko, Stephanie Lobaugh, Elena Mead, Gunjan L. Shah, Sergio Giralt, Miguel-Angel Perales, Michael Scordo, Parastoo B. Dahi, Josel D. Ruiz, Beatriz Korc-Grodzicki, Richard J. Lin, Craig S. Sauter, Hei Ton Chan, Martina Pennisi, Mari Lynne Silverberg, Bianca Santomasso, Paul A. Hamlin, Chelsea A Brooklyn, Sean M. Devlin, and M. Lia Palomba

Subjects
medicine.medical_treatment, Antigens, CD19, Cell- and Tissue-Based Therapy, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, CD19, Antigen, medicine, Humans, Letters to the Editor, B-cell lymphoma, Receptor, Aged, Receptors, Chimeric Antigen, biology, business.industry, Hematology, Immunotherapy, medicine.disease, Lymphoma, Relapsed refractory, biology.protein, Cancer research, Chimeric Antigen Receptor T-Cell Therapy, Lymphoma, Large B-Cell, Diffuse, business
Published
2020

4. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

Author

Colette Owens, Augustine Iannotta, Paul A. Hamlin, Gilles Salles, Beatriz Korc-Grodzicki, Matthew J. Matasar, Mayan Oliveros, Ariela Noy, Dylan L Schick, Craig H. Moskowitz, Pamela Drullinsky, Philip Caron, John F. Gerecitano, Esther Drill, Andrew D. Zelenetz, Anita Kumar, and Richard J. Lin

Subjects
Oncology, medicine.medical_specialty, Aging, Pilot Projects, Newly diagnosed, immune system diseases, Prednisone, hemic and lymphatic diseases, Internal medicine, Activities of Daily Living, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective Studies, Cyclophosphamide, Aged, Cytokine milieu, business.industry, Hematology, Middle Aged, medicine.disease, Lymphoma, Treatment Outcome, Doxorubicin, Vincristine, Treatment strategy, Cytokines, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, medicine.drug
Abstract

Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as functional limitation, multimorbidity, or cognitive deficits. In this prospective pilot study, we evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL, defined by either age ≥70 years or age 60-70 years with Karnofsky performance scale (KPS)

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results